Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Asklepion Pharmaceuticals, LLC
Modality
UNKNOWN
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06989567CT.gov A Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis | — | Not Yet Recruiting | — | — | — |
NCT06635902CT.gov Intravenous L-Citrulline for Vaso-occlusive Pain Episode in Sickle Cell Disease | — | Recruiting | — | — | — |
NCT02659644CT.gov A Study of Oral L-citrulline in Sickle Cell Disease | — | Withdrawn | — | — | — |
NCT00343954CT.gov PK and PD Responses to Oral L-Citrulline in Patients With Sickle Cell Disease | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Sickle Cell Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| L-Citrulline (this asset) | Asklepion Pharmaceuticals, LLC | P3 | B · 60 |
| Glutamine | Ain Shams University | P4 | BBB |
| Hydroxyurea | St. Jude Children's Research Hospital | P4 | BB |
| Crizanlizumab | Novartis Pharmaceuticals | P4 | BB |
| Magnesium Metallicum | Medical College of Wisconsin | P3 | BB |
| Nivestim | St. Jude Children's Research Hospital | P4 | BB |
| Nepenthe | Oman Medical Speciality Board | P4 | BB |
| ARG | Tanta University | P3 | BB |
| Fentanyl | University College Dublin | P4 | BB |
+42 more in the Sickle Cell Disease cohort
Other indications for L-Citrulline
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Becker Muscular Dystrophy | — | P2 | B · 57 |
| Essential Hypertension | — | P1 | CC · 47 |
| MELAS Syndrome | — | P1 | CC · 47 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. L-Citrulline in Sickle Cell Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/l-citrulline-sickle-cell-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →